Regeneron Pharmaceuticals 8-K Report: Key Developments for Investors

From the provided section of the financial report, here are the key pieces of information extracted:

1. Entity Information:

• Company Name: Regeneron Pharmaceuticals, Inc.
• CIK (Central Index Key): 0000872589
• SEC File Number: 000-19034
• EIN (Employer Identification Number): 13-3444607
• Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
• Contact Number: 914-847-7000

2. Filing Information:

• Filing Type: 8-K (Current Report)
• Filing Date: October 28, 2025
• Reporting Period: October 28, 2025 (indicating a specific event or development reported on this date)

3. Stock Information:

• Type of Security: Common Stock
• Par Value: $0.001 per share
• Ticker Symbol: REGN
• Exchange: NASDAQ

4. Other Notes:

• The report is filed in XBRL format, which is commonly used for financial reporting to allow for easier data analysis.

Insights:

• The report is a current report (8-K), which typically indicates a significant event or change that shareholders and the SEC should be aware of. The timing suggests it may relate to new developments or announcements made by Regeneron Pharmaceuticals on the same day.
• The common stock information indicates that the company is publicly traded, which can be relevant for investors and analysts tracking its performance.
• The filing indicates a formal communication to the SEC, reflecting regulatory compliance and transparency in financial reporting.

This information could be further analyzed in the context of market performance, investor sentiment, and the specific event reported in the 8-K filing.